Molecular mechanism of vacuolar formation associated with cell death induced by CDK4/6 inhibitor abemaciclib

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Tanaka, Yoshinori [2 ]
Okimoto, Tomoya [1 ]
Ikeda, Toshikatsu [1 ]
Hara, Tomoyo [1 ]
Takeya, Kosuke [2 ]
Takano, Naoharu [3 ]
Hiramoto, Masaka [3 ]
Aizawa, Shin [1 ]
Miyazawa, Keisuke [3 ]
Eto, Masumi [2 ]
Hirai, Shuichi [1 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morphol, Sch Med, Tokyo, Japan
[2] Okayama Univ Sci, Dept Vet Med, Biochem Unit, Okayama, Japan
[3] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3317
引用
收藏
页码：1741 / 1741
页数：1
相关论文
共 50 条
  • [21] CDK4 & 6 inhibitor Abemaciclib exerts intrinsic immunomodulatory effects on human T cells in vitro
    Chin, Darin
    Carpenito, Carmine
    Amaladas, Nelusha
    Chung, Linda
    Staschke, Kirk
    Schaer, David
    Beckmann, Richard
    Novosiadly, Ruslan
    Kalos, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [22] Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells
    Abutorabi, Elaheh Seyed
    Irani, Shiva
    Yaghmaie, Marjan
    Ghaffari, Seyed Hamid
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2020, 8 (04): : 438 - 445
  • [23] Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo
    Naz, Sarwat
    Sowers, Anastasia
    Choudhuri, Rajani
    Wissler, Maria
    Gamson, Janet
    Mathias, Askale
    Cook, John A.
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3994 - 4005
  • [24] CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma
    Mcgregor, Bradley A.
    Xie, Wanling
    Berg, Stephanie A.
    Xu, Wenxin
    Viswanathan, Srinivas R.
    Mcdermott, David
    Signoretti, Sabina
    Kaelin, William G.
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2025, 23 (03)
  • [25] Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
    Dickson, Mark Andrew
    Koff, Andrew
    D'Angelo, Sandra P.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Kelly, Ciara Marie
    Chi, Ping
    Antonescu, Cristina R.
    Landa, Jonathan
    Qin, Li-Xuan
    Crago, Aimee Marie
    Singer, Samuel
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
    O'Brien, Neil A.
    McDermott, Martina S.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Loson, Oliver
    Chau, Kevin
    Jia, Weiping
    Kamranpour, Naeimeh
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Glaspy, John A.
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [28] Biomarkers for CDK4/6 inhibitor efficacy
    Sorscher, Steven
    BREAST JOURNAL, 2021, 27 (01): : 103 - 103
  • [29] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Wolf, Martin
    de Guibert, Sophie
    Zettl, Florian
    Hahka-Kemppinen, Marjo
    Wang, David Xiaohui
    Brueck, Patrick
    Caldwell, Charles
    Beckmann, Richard
    Gelbert, Lawrence
    Cronier, Damien
    Lin, Ji
    Li, Lily
    Chan, Edward M.
    Pfreundschuh, Michael
    Wilhem, Martin
    Hess, Georg
    BLOOD, 2014, 124 (21)
  • [30] CDK4/6 inhibitor abemaciclib has been established in early as well as locally advanced and metastatic settings
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 156 - 157
12345